ARA-290 (Cibinetide) vs Thymosin Alpha 1

ARA-290 (Cibinetide)

ARA-290, also called cibinetide, is an 11-residue synthetic peptide modelled on the helix B surface of erythropoietin. Erythropoietin is best known as the hormone that drives red blood cell production, but it also acts on other tissues, and ARA-290 was designed to probe that second set of actions without the effect on blood. Its N-terminal glutamine is cyclised to pyroglutamate, which is why it also appears in the literature as pyroglutamate helix B surface peptide. Most studies are in cell and rodent models of nerve injury, inflammation and metabolic disease. It has also been tested in small, early-phase human trials, including in neuropathy associated with sarcoidosis and with diabetes, and human data remain limited.

Thymosin Alpha 1

Thymosin alpha 1 is a 28-residue peptide, acetylated at its N-terminus, first isolated from calf thymus extract and now made synthetically. It matches the N-terminal segment of a larger protein, prothymosin alpha, from which it is thought to be released by proteolytic processing; the synthetic form is also known as thymalfasin. The peptide is strongly acidic and, in water, largely unstructured. Its literature spans cell studies of immune signalling, animal infection and tumour models, and human clinical studies in chronic viral hepatitis, severe infection and vaccine response. Many of those clinical studies are small, and a defined cellular receptor has not been confirmed.

How ARA-290 (Cibinetide) acts

Erythropoietin acts on red-cell precursors through a homodimer of its receptor (EPOR). A different receptor, proposed to be EPOR paired with the beta-common receptor subunit (CD131), has been suggested to mediate its actions outside the blood-forming system. ARA-290 reproduces the helix B face of erythropoietin, which is thought to engage this proposed complex but not the classical homodimer, and it has been reported not to stimulate red-cell production in animal studies. Cell and rodent work has examined its influence on inflammatory cytokine signalling and apoptosis. The make-up and role of the proposed receptor remain debated.

How Thymosin Alpha 1 acts

Thymosin alpha 1 has no single confirmed receptor. Several studies have linked its activity to Toll-like receptor signalling, particularly TLR9 and TLR2 in dendritic cells, with downstream activation of pathways including NF-κB and p38 MAPK. In cell and animal models it has been reported to influence T-cell maturation, production of cytokines such as interleukin-2 and interferon-gamma, and natural killer cell activity. Structural studies report that it becomes partly helical in membrane-like environments, which has been proposed as relevant to how it interacts with cells, though this remains an open question.

The records side by side

• Type: ARA-290 (Cibinetide), Synthetic undecapeptide; Thymosin Alpha 1, Acetylated thymic peptide
• Length: ARA-290 (Cibinetide), 11 amino acids; Thymosin Alpha 1, 28 amino acids
• Molecular weight: ARA-290 (Cibinetide), 1257.3 g/mol; Thymosin Alpha 1, 3108.3 g/mol
• Molecular formula: ARA-290 (Cibinetide), C51H84N16O21; Thymosin Alpha 1, C129H215N33O55

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.